Atlantic Union Bankshares Corp Sells 830 Shares of Medtronic Plc (NYSE:MDT)
Atlantic Union Bankshares Corp Sells 830 Shares of Medtronic Plc (NYSE:MDT)
Atlantic Union Bankshares Corp reduced its stake in shares of Medtronic plc (NYSE:MDT – Get Rating) by 1.1% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 77,822 shares of the medical technology company's stock after selling 830 shares during the period. Atlantic Union Bankshares Corp's holdings in Medtronic were worth $6,984,000 at the end of the most recent reporting period.
大西洋联合银行股份有限公司最近提交给美国证券交易委员会的文件显示,该公司在第二季度减持了美敦力股份(纽约证券交易所代码:MDT-GET评级)1.1%。在此期间出售了830股后,该公司持有这家医疗技术公司77,822股股票。在最近一次报告期结束时,大西洋联合银行持有的美敦力股份价值6984,000美元。
Other institutional investors and hedge funds have also recently modified their holdings of the company. Chase Investment Counsel Corp raised its position in Medtronic by 2.9% during the 1st quarter. Chase Investment Counsel Corp now owns 3,220 shares of the medical technology company's stock worth $357,000 after buying an additional 90 shares during the last quarter. Wedge Capital Management L L P NC increased its holdings in shares of Medtronic by 3.6% during the 1st quarter. Wedge Capital Management L L P NC now owns 2,633 shares of the medical technology company's stock valued at $292,000 after purchasing an additional 92 shares in the last quarter. Main Street Financial Solutions LLC increased its holdings in shares of Medtronic by 0.9% during the 1st quarter. Main Street Financial Solutions LLC now owns 9,944 shares of the medical technology company's stock valued at $1,103,000 after purchasing an additional 92 shares in the last quarter. Rosenberg Matthew Hamilton increased its holdings in shares of Medtronic by 7.9% during the 1st quarter. Rosenberg Matthew Hamilton now owns 1,286 shares of the medical technology company's stock valued at $143,000 after purchasing an additional 94 shares in the last quarter. Finally, Riverwater Partners LLC increased its holdings in shares of Medtronic by 2.2% during the 1st quarter. Riverwater Partners LLC now owns 4,527 shares of the medical technology company's stock valued at $502,000 after purchasing an additional 99 shares in the last quarter. 79.81% of the stock is owned by institutional investors.
其他机构投资者和对冲基金最近也调整了对该公司的持股。大通投资顾问公司(Chase Investment Counsel Corp)在第一季度将其在美敦力的头寸提高了2.9%。大通投资顾问公司(Chase Investment Counsel Corp)目前持有这家医疗技术公司3,220股股票,价值357,000美元,此前该公司在上个季度又购买了90股。韦奇资本管理公司L L P NC在第一季度增持了3.6%的美敦力股票。Wdge Capital Management L L P NC现在拥有这家医疗技术公司2,633股股票,价值29.2万美元,此前在上个季度又购买了92股。Main Street Financial Solutions LLC在第一季度增持了0.9%的美敦力股票。Main Street Financial Solutions LLC在上个季度又购买了92股后,现在拥有9944股这家医疗技术公司的股票,价值1,103,000美元。罗森博格马修·汉密尔顿在第一季度增持了7.9%的美敦力股票。罗森博格·马修·汉密尔顿现在拥有这家医疗技术公司1,286股股票,价值143,000美元,上个季度又购买了94股。最后,Riverwater Partners LLC在第一季度增持了2.2%的美敦力股票。Riverwater Partners LLC现在拥有这家医疗技术公司4527股股票,价值50.2万美元,上个季度又购买了99股。79.81%的股票由机构投资者持有。
Analyst Upgrades and Downgrades
分析师升级和下调评级
MDT has been the topic of a number of research analyst reports. Raymond James cut shares of Medtronic from an "outperform" rating to a "market perform" rating in a research note on Wednesday, August 24th. Wolfe Research started coverage on shares of Medtronic in a research note on Tuesday, July 5th. They set an "underperform" rating and a $85.00 target price on the stock. Piper Sandler lowered their target price on shares of Medtronic from $100.00 to $90.00 in a research note on Tuesday, August 23rd. Truist Financial lowered their target price on shares of Medtronic from $111.00 to $97.00 and set a "hold" rating on the stock in a research note on Wednesday, July 20th. Finally, Stifel Nicolaus lowered their target price on shares of Medtronic from $125.00 to $105.00 in a research note on Monday, July 18th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Medtronic presently has an average rating of "Hold" and an average price target of $111.52.
MDT已经成为许多研究分析师报告的主题。8月24日,雷蒙德·詹姆斯在一份研究报告中将美敦力的股票评级从“跑赢大盘”下调至“市场表现”。Wolfe Research在7月5日星期二的一份研究报告中开始报道美敦力的股票。他们为该股设定了“表现不佳”的评级和85.00美元的目标价。派珀·桑德勒在8月23日周二的一份研究报告中将美敦力的目标股价从100.00美元下调至90美元。7月20日,Truist Financial在一份研究报告中将美敦力股票的目标价从111.00美元下调至97.00美元,并将该股的评级设定为持有。最后,Stifel Nicolaus在7月18日星期一的一份研究报告中将美敦力的目标股价从125.00美元下调至105.00美元。一名分析师对该股的评级为卖出,11名分析师给出了持有评级,8名分析师给出了该公司的买入评级。根据MarketBeat.com的数据,美敦力目前的平均评级为“持有”,平均目标价为111.52美元。
Medtronic Stock Performance
美敦力股票表现
Medtronic (NYSE:MDT – Get Rating) last announced its quarterly earnings results on Tuesday, August 23rd. The medical technology company reported $1.13 earnings per share for the quarter, beating analysts' consensus estimates of $1.12 by $0.01. The business had revenue of $7.37 billion during the quarter, compared to analysts' expectations of $7.20 billion. Medtronic had a return on equity of 13.64% and a net margin of 16.75%. During the same quarter last year, the business posted $1.41 earnings per share. As a group, analysts expect that Medtronic plc will post 5.53 EPS for the current fiscal year.
美敦力(纽约证券交易所代码:MDT-GET评级)最近一次公布季度收益是在8月23日,星期二。这家医疗技术公司公布本季度每股收益为1.13美元,比分析师普遍预期的1.12美元高出0.01美元。该业务当季营收为73.7亿美元,高于分析师预期的72亿美元。美敦力的股本回报率为13.64%,净利润率为16.75%。去年同一季度,该公司公布的每股收益为1.41美元。分析师预计,作为一个整体,美敦力本财年每股收益将达到5.53欧元。
Medtronic Dividend Announcement
美敦力股息公告
The business also recently declared a quarterly dividend, which will be paid on Friday, October 14th. Investors of record on Friday, September 23rd will be given a dividend of $0.68 per share. This represents a $2.72 annualized dividend and a yield of 3.30%. The ex-dividend date is Thursday, September 22nd. Medtronic's dividend payout ratio (DPR) is presently 70.28%.
该公司最近还宣布了季度股息,将于10月14日(星期五)支付。9月23日(星期五)登记在册的投资者将获得每股0.68美元的股息。这意味着年化股息为2.72美元,收益率为3.30%。除息日期为9月22日(星期四)。美敦力的股息支付率(DPR)目前为70.28%。
About Medtronic
美敦力简介
(Get Rating)
(获取评级)
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
美敦力开发、制造和销售基于设备的医疗疗法,面向世界各地的医疗系统、医生、临床医生和患者。其心血管产品组合提供植入式心脏起搏器、心律转复除颤器和心脏再同步治疗设备;心脏消融产品;可插入式心脏监测系统;TYRX产品;以及远程监测和以患者为中心的软件。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Medtronic (MDT)
- This Is A Memorable Time To Buy Into Micron Technology
- Thor Industries Hammers Out A Bottom
- Let Paychex Stock Work Hard For You
- Declining Profits Challenge the CarMax Value Proposition
- How Does Keurig Dr Pepper Compare To Larger Rivals Coke & Pepsi?
- 免费获取StockNews.com关于美敦力(MDT)的研究报告
- 这是买入美光科技的难忘时刻
- 雷神工业走出谷底
- 让Paychex股票为您努力工作
- 利润下降对CarMax价值主张的挑战
- Keurig Dr Pepper与规模更大的竞争对手可口可乐(Coke&Pepsi)相比如何?
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
接受美敦力日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收最新新闻和分析师对美敦力及相关公司评级的每日摘要。